149 related articles for article (PubMed ID: 37673738)
1. KRT72 might serves as a prognostic biomarker for patients with prostate cancer.
Wang J; Xiao Y; Yu Q; Zhang C
Asian J Surg; 2023 Nov; 46(11):5382-5384. PubMed ID: 37673738
[No Abstract] [Full Text] [Related]
2. ZMYND10 could serve as a prognostic biomarker for patients with prostate cancer.
Wang J; Xiao Y; Li D; Zhang C
Asian J Surg; 2023 Nov; 46(11):5376-5378. PubMed ID: 37673741
[No Abstract] [Full Text] [Related]
3. Identification of Novel Diagnostic Biomarkers in Prostate Adenocarcinoma Based on the Stromal-Immune Score and Analysis of the WGCNA and ceRNA Network.
Zhang T; Wang Y; Dong Y; Liu L; Han Y; Wang H; Wei Q; Xia P; Ma W; Li L
Dis Markers; 2022; 2022():1909196. PubMed ID: 35075375
[TBL] [Abstract][Full Text] [Related]
4. TEX19 could function as a prognostic biomarker for prostate cancer.
Xiao Y; Wang J; Feng D; Zhang C
Asian J Surg; 2023 Dec; 46(12):5671-5673. PubMed ID: 37648546
[No Abstract] [Full Text] [Related]
5. ORC6, a novel prognostic biomarker, correlates with T regulatory cell infiltration in prostate adenocarcinoma: a pan-cancer analysis.
Lin Y; Zhang Y; Tuo Z; Gao L; Ding D; Bi L; Yu D; Lv Z; Wang J; Chen X
BMC Cancer; 2023 Mar; 23(1):285. PubMed ID: 36978046
[TBL] [Abstract][Full Text] [Related]
6. Immune-related biomarker risk score predicts prognosis in prostate cancer.
Liu Z; Zhong J; Cai C; Lu J; Wu W; Zeng G
Aging (Albany NY); 2020 Nov; 12(22):22776-22793. PubMed ID: 33197890
[TBL] [Abstract][Full Text] [Related]
7. A prognostic signature consisting of metabolism-related genes and SLC17A4 serves as a potential biomarker of immunotherapeutic prediction in prostate cancer.
Li H; Gu J; Tian Y; Li S; Zhang H; Dai Z; Wang Z; Zhang N; Peng R
Front Immunol; 2022; 13():982628. PubMed ID: 36325340
[TBL] [Abstract][Full Text] [Related]
8. Nur77 Serves as a Potential Prognostic Biomarker That Correlates with Immune Infiltration and May Act as a Good Target for Prostate adenocarcinoma.
Hu QY; Liu J; Zhang XK; Yang WT; Tao YT; Chen C; Qian YH; Tang JS; Yao XS; Xu YH; Wang JH
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770929
[TBL] [Abstract][Full Text] [Related]
9. IL-8 Produced Via Bidirectional Communication Between Prostate Cancer and M2 Macrophages as a Potential Diagnostic and Prognostic Biomarker.
Fan H; Tang Z; Tian Y; Lv Q; Zeng F
Technol Cancer Res Treat; 2023; 22():15330338231177809. PubMed ID: 37226533
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.
Lamy PJ; Allory Y; Gauchez AS; Asselain B; Beuzeboc P; de Cremoux P; Fontugne J; Georges A; Hennequin C; Lehmann-Che J; Massard C; Millet I; Murez T; Schlageter MH; Rouvière O; Kassab-Chahmi D; Rozet F; Descotes JL; Rébillard X
Eur Urol Focus; 2018 Dec; 4(6):790-803. PubMed ID: 28753865
[TBL] [Abstract][Full Text] [Related]
11. Ki-67 Remains Solely a Prognostic Biomarker in Localized Prostate Cancer.
Spratt DE
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):513-515. PubMed ID: 29893267
[No Abstract] [Full Text] [Related]
12. Development and Validation of an Individualized Immune Prognostic Signature for Recurrent Prostate Cancer.
Jin Y; Wang L; Lou H; Song C; He X; Ding M
Comb Chem High Throughput Screen; 2021; 24(1):98-108. PubMed ID: 32593277
[TBL] [Abstract][Full Text] [Related]
13. CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.
Bastos DA; Antonarakis ES
Expert Rev Mol Diagn; 2018 Feb; 18(2):155-163. PubMed ID: 29319382
[TBL] [Abstract][Full Text] [Related]
14. The role of caveolin-1 in prostate cancer: clinical implications.
Thompson TC; Tahir SA; Li L; Watanabe M; Naruishi K; Yang G; Kadmon D; Logothetis CJ; Troncoso P; Ren C; Goltsov A; Park S
Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):6-11. PubMed ID: 19581923
[TBL] [Abstract][Full Text] [Related]
15. Tissue biomarkers for prognosis of prostate cancer: a systematic review and meta-analysis.
Zhao L; Yu N; Guo T; Hou Y; Zeng Z; Yang X; Hu P; Tang X; Wang J; Liu M
Cancer Epidemiol Biomarkers Prev; 2014 Jun; 23(6):1047-54. PubMed ID: 24636974
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.
Fredsøe J; Rasmussen AKI; Thomsen AR; Mouritzen P; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Eur Urol Focus; 2018 Dec; 4(6):825-833. PubMed ID: 28753866
[TBL] [Abstract][Full Text] [Related]
17. Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment.
Moradi A; Srinivasan S; Clements J; Batra J
Cancer Metastasis Rev; 2019 Sep; 38(3):333-346. PubMed ID: 31659564
[TBL] [Abstract][Full Text] [Related]
18. GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
Jeyapala R; Savio AJ; Olkhov-Mitsel E; Kamdar S; Zhao F; Cuizon C; Liu RSC; Zlotta A; Fleshner N; van der Kwast T; Bapat B
Eur Urol Oncol; 2019 May; 2(3):231-238. PubMed ID: 31200836
[TBL] [Abstract][Full Text] [Related]
19. New biomarkers for diagnosis and prognosis of localized prostate cancer.
Chistiakov DA; Myasoedova VA; Grechko AV; Melnichenko AA; Orekhov AN
Semin Cancer Biol; 2018 Oct; 52(Pt 1):9-16. PubMed ID: 29360504
[TBL] [Abstract][Full Text] [Related]
20. Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors.
Andersen LB; Nørgaard M; Rasmussen M; Fredsøe J; Borre M; Ulhøi BP; Sørensen KD
J Pathol; 2021 Oct; 255(2):155-165. PubMed ID: 34255349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
